List of Caspofungin Acetate drug patents

Caspofungin Acetate is owned by Fresenius Kabi Usa.

Caspofungin Acetate contains Caspofungin Acetate.

Caspofungin Acetate has a total of 1 drug patent out of which 0 drug patents have expired.

Caspofungin Acetate was authorised for market use on 30 December, 2016.

Caspofungin Acetate is available in powder;intravenous dosage forms.

The generics of Caspofungin Acetate are possible to be released after 21 December, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(9 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in